DOCSLIB.ORG

WC No. Date of Issue Valid Till Name of the Firm Address of the Firm Name of Products Irbesartan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WC No. Date of Issue Valid Till Name of the Firm Address of the Firm Name of Products Irbesartan WC No. Date of Issue Valid Till Name of the Firm Address of the Firm Name of Products Irbesartan (EP) Desfesoterodine Succinate (IH) Clopidogrel Bisulphate USP/EP Olmesartan Medoxomil IH Clarithromycin EP 24.05.2016 Losartan Potassium EP Q-1-4, Industrial area ,Ghinrongi WC-0001 13.06.2016 14.05.2019 M/s Teva API INDIA LTD Atorvastatin Calcium EP Malanpur -477 117, Dist -Bhind (MP) 16.02.2017 Quetiapine Fumarate IH Sitagliptin Malate IH Sitagliptin Phosphate IH Dabigatrante Etexilate Mesylate IH Ticagrelor IH Desvenlafaxine Base Famciclovir( IH/USP) Fluvastatin Sodium (IH/USP/EP) Olanzapine(IH/ USP/EP) Irbesartan( IH/USP/EP) Montelukast Sodium(( IH/USP/EP) Quetiapine Fumarate( IH/USP) Diltiazem Hydrochloride(IH/USP/EP) A-2, A-2/1, A-2/2, UPSIDC Industrial Ezetimibe(IH/USP) 22.08.2016 WC-0002 27.05.2019 M/s. Teva API India PVT. Ltd., Area-II, Gajraula-244 235, Dist., J.P. Sertraline Hydrochloride(IH/USP/EP) 07.03.2018 Nagar (U.P) Pioglitazone Hydrochloride(IH/USP/EP) Valsartan(IH/USP/EP) Losartan Potassium(IH/USP/EP) Pregabalin(IH/USP/EP) Atorvastatin Calcium(IH/USP) Caspofungin Acetate(IH) Eletriptan Hydrobromide (IH) Rosuvastatin Calcium (IH/EP) Acamprosate Calcium (Ph. Eur.) Anastrozole (USP/Ph. Eur./IH) Aripiprazole (USP/Ph. Eur.) Atorvastatin Calcium Trihydrate (USP/Ph. Eur./JP) Cinacalcet Hydrochloride (IH) Clarithromycin (USP/Ph. Eur./BP/JP) Clarithromycin Citrate (IH) Clarithromycin Granules 27.5%, 33% & 42% (IH) Clopidogrel Hydrochloride (IH) Clopidogrel Hydrogen Sulphate or Clopidogrel Bisulphate (USP/Ph. Eur.) Colesevelam Hydrochloride (USP) Dapoxetine Hydrochloride (IH) Donepezil Hydrochloride (USP/Ph. Eur./IH) Dutasteride (Ph. Eur.) Ezetimibe (IH) Vill.- Bhagwanpur, Barwala Road, Near Fexofenadine Hydrochloride (USP/Ph. WC-0003 01.06.2016 27.05.2019 M/s. Ind- Swift Laboratories Ltd., Dera Bassi, Distt.- SAS Nagar (Mohali), Eur./BP/JP) Punjab Imatinib Mesylate (IH) Imatinib Mesylate Granules (IH) Ivabradine Hydrochloride (IH) Letrozole (USP/Ph. Eur.) Mecloxamine Citrate (IH) Naratriptan Hydrochloride (USP) Nateglinide (USP/Ph. Eur./JP) Pioglitazone Hydrochloride (USP/Ph. Eur./JP/IH) Quetiapine Fumarate (USP/Ph. Eur./IH) Risedronate Sodium 2.5 Hydrate (USP/Ph. Eur.) Ropinirole Hydrochloride (USP/Ph. Eur./IH) Telmisartan (USP/Ph. Eur./JP) Temozolomide (USP) Valganciclovir Hydrochloride (USP) Ivabradine Oxalate (IH M/s. IOL Chemicals and Village Fatehgarh Chana, Mansa Road, Lamotrigine (IP/BP/USP/Ph. Eur) WC-0004 30.05.2016 27.05.2019 Pharmaceuticals Ltd., Barnala, Punjab Ibuprofen IP/BP/USP/Ph Eur./JP Gajraula Chandpur Road, Dhaunara- Peppermint Oil (Ph.Eur) WC-0005 08.06.2016 27.05.2019 M/s. Norex Flavours Pvt. Ltd., 244 231, Dist.- J. P. Nagar (Uttar Levomenthol (Ph.Eur) Pradesh) Gajraula Chandpur Road, Dhaunara- WC-0005 08.06.2016 27.05.2019 M/s. Norex Flavours Pvt. Ltd., 244 231, Dist.- J. P. Nagar (Uttar Pradesh) Mint Oil Partly Dementholised (Ph.Eur) Colchicine (EP/USP) Digoxin (EP/USP) Hyoscine Butylbromide (EP) Hyoscine Hydrobromide (EP) Scopolamine Hydrobromide (USP) Hyoscyamine Hydrobromide (USP) Nicotine (EP/USP) Nicotine Polacrilex (USP) Nicotine Resinate (EP) Reserpine (EP/USP) Thiocolchicoside (FP/IH) Vinpocetine (EP/USP) Yohimbine Hydrochloride (EP/USP) Benzethonium Chloride (USP) 15.06.2016 25/2, Main Mathura Road, Village Kalli, M/s. Alchem International Cimetropium Bromide (IH) WC-0006 30.06.2016 27.05.2019 Ballabgarh, Faridabad-121 004, Pvt.Ltd. 22.08.2016 Haryana Paclitaxel (EP/USP) Quinine Dihydrochloride (BP) Quinine Sulphate (EP/USP) Silymarin extract (IH) Atropine Sulphate (IP) Atropine Sulfate (BP/EP/USP) Hyoscyamine Sulphate (IP/BP/EP/USP) Enoxolone (EP) Homatropine Methyl Bromide (USP/EP) Vincamine (FP/IH) Methscopolamine Bromide (USP) Nicotine Ditartrate Dihydrate (EP) Centella Asiatica Triterpenes (USP) Atropine Sulphate Hydrate (JP) Hyoscine (Ph.Eur) Niacin (IP/USP) F-271 (A), Road No. 12, Mewad Niacinamide (IP/USP) WC-0007 03.08.2016 27.05.2019 M/s. Western Drugs Ltd., Industrial Area, Madri, Udaipur-313 003 Nicotinic Acid (BP/EP/JP) Nicotinamide (BP/EP/JP) Cefixime Trihydrate (IH) Cefpodoxime Proxetil (IH) Village Sundhran PO Mubarakpur, Dera WC-0008 10.08.2016 27.05.2019 M/s. Parabolic Drugs Ltd., Cefuroxime Axetil (amorphous) (IH) Bassi, Punjab Cefdinir (IH) Cefprozil (IH) Fluticasone Furoate IH Mometasone Furoate (BP/EP/USP) Budesonide (BP/EP/USP) Isoflupredone Acetate (USP) Formoterol Fumarate Dihydrate (BP/EP) Salmeterol Xinafoate (BP/EP) 12.07.2016 55-57, HSIDC Industrial Estate, Murthal WC-0009 27.05.2019 M/s. Coral Drugs Pvt. Ltd., Fluticasone Propionate (BP/EP/USP/IP) 13.06.2018 Sonepat Azelastine HCl (BP/EP/IP) Esrtamustine Sodium Phosphate (BP) Flutamide (EP/USP) Danazole (USP) Ciclesonide (IP) Triamcinolone Acetonide (IP/USP/EP) Amoxicillin Trihydrate (IP/BP/USP/Ph.Eur.) Ampicillin Trihydrate (IP/BP/USP/Ph.Eur.) 04.07.2016, M/s. DSM Sinochem Toansa, Dist. Nawanshahar - 144 533, WC-0010 27.05.2019 03.08.2016, 06.02.2017 Pharmaceuticals India Pvt. Ltd., Punjab, India Cloxacillin Sodium (IP/BP/USP/Ph.Eur.) Flucloxacillin Sodium (BP/USP/Ph.Eur) Oxacillin Sodium (USP/Ph.Eur) Amorolfine Hydrochloride (IH) Atorvastatin Calcium Trihydrate (USP/Ph.Eur.) Benazepril Hydrochloride (USP/Ph.Eur.) Bosentan Monohydrate (IH) Candesartan Cilexetil (Ph.Eur./IH) Celiprolol Hydrochloride (Ph.Eur.) Desloratadine (Ph.Eur. /IH) Donepezil Hydrochloride (USP/IH) Doxycycline Hyclate (USP / Ph.Eur). Entecavir Monohydrate (IH) Eslicarbazepine Acetate (IH) Esomeprazole Magnesium Trihydrate (USP) Village Toansa, P.O. Rail Majra, M/s. Sun Pharmaceutical District S.B.S. Nagar Industries Limited, WC-0011 06.06.2016 27.05.2019 (Nawanshahar) - 144 533, Punjab, India. Febuxostat (IH) Fexofenadine Hydrochloride (USP/Ph.Eur./IH) Fluvastatin Sodium (IH/Ph. Eur.) Irbesartan (USP/Ph.Eur.) Isotretinoin (USP/Ph.Eur.) Lacosamide (IH) Village Toansa, P.O. Rail Majra, Lansoprazole (USP/Ph.Eur.) M/s. Sun Pharmaceutical District S.B.S. Nagar Industries Limited, Levofloxacin (USP /IH) WC-0011 06.06.2016 27.05.2019 (Nawanshahar) - 144 533, Punjab, India. Midazolam (USP/Ph.Eur.) Nevirapine (Anhydrous) (USP /Ph.Eur.) Ofloxacin (USP/Ph.Eur.) Olanzapine (USP/Ph.Eur. /IH) Omeprazole Magnesium (USP/Ph.Eur.) Pantoprazole Sodium (Sesquihydrate) (USP) Rabeprazole Sodium (IH) Ramipril (USP/Ph.Eur.) Repaglinide (USP/Ph.Eur.) Sertraline Hydrochloride Ph.Eur. Simvastatin (USP/Ph.Eur.) Solifenacin Succinate (IH) Tamsulosin Hydrochloride (USP/Ph.Eur.) Telmisartan (USP/Ph.Eur.) Tramadol Hydrochloride (Ph.Eur.) Valganciclovir Hydrochloride (USP/IH) Valsartan (USP/Ph. Eur.) Venlafaxine Hydrochloride (Ph.Eur.) Voriconazole (Ph.Eur.) Cilazapril (Ph.Eur) Pioglitazone HCl (Extra Pure) USP/IH Donepezil Hydrochloride USP/IH Clopidogrel Bisulfate USP Bivalirudin(IH) Sevelamer Hydrochloride (IH) Letrozole Ph. Eur./USP Entacapone IH/Ph. Eur. Imiquimod (IH/USP) Naratriptan Hydrochloride (IH/USP) Olopatadine Hydrochloride USP/IH Trimetazidine Dihydrochloride Ph. Eur. Irbesartan Ph. Eur./ IH/USP Zoledronic Acid IH Sevelamer Carbonate IH Eptifibatide IH Clopidogrel Hydrogen Sulfate Ph. Eur. B-1/8, MIDC Late Parshuram Indl Area, WC-0012 30.05.2016 27.05.2019 M/s. USV Ltd., Tal - Khed, Dist.- Ratnagiri Linezolid IH Octreotide Acetate IH Nateglinide USP Glatiramer Acetate (Concentrate Solution) IH Metformin Hydrochloride (BP/USP/Ph.Eur.) Glibenclamide Ph. Eur. Glipizide (BP/ Ph. Eur. /USP) Nimodipine BP/Ph. Eur. Nitrendipine BP/Ph. Eur. Pioglitazone Hydrochloride (BP/USP/Ph.Eur/IH) Repaglinide Ph. Eur. USP Ropinirole Hydrochloride (IH/USP) Glimepiride (USP/Ph. Eur./IH) Bicalutamide (IH/Ph.Eur/USP) Acitretin Ph.Eur/USP Amlodipine Besylate Ph. Eur/USP/BP Amlodipine Maleate IH Sy No. 174 to 176, IDA, Bollaram S (-) Amlodipine Besilate IH WC-0013 05.08.2016 02.07.2019 M/s. Glochem Industries Ltd., Village, Medak District, Telangana State, India Cetrizine Dihydrochloride Ph.Eur/USP Carbidopa Ph.Eur/USP Anastrazole (IH/USP/Ph. Eur.) Armodafinil (IH) Bosentan Monohydrate (IH) Unit-I, Sy. No. 174-176, IDA , Bollaram, WC-0014 08.05.2016 27.05.2019 M/s. Natco Pharma Ltd, Medak Dist., AP Citalopram Hydrobromide (USP/Ph. Eur.) Clozapine (USP/Ph. Eur.) Deferasirox (IH) Escitalopram Oxalate (IH/USP.) Erlotinib Hydrochloride (IH) Granisetron Hydrochloride (USP/Ph. Eur.) Glatiramer Acetate (IH) Gefitinib (IH) Ibandronate Sodium Monohydrate (IH) Imatinid Mesylate (IH/Ph. Eur.) Lansoprazole (USP/Ph. Eur.) Letrozole (USP/Ph. Eur.) Lanthanum Carbonate Dihydrate (IH) Unit-I, Sy. No. 174-176, IDA , Bollaram, WC-0014 08.05.2016 27.05.2019 M/s. Natco Pharma Ltd, Ledipasvir (IH) Medak Dist., AP Omeprazole (USP/Ph. Eur.) Ondansetron Hydrochloride (USP) Ondansetron Hydrochloride Dihydrate (Ph. Eur.) Pantoprazole Sodium Sesquihydrate (IH/USP/Ph. Eur.) Rizatriptan Bezoate (IH/USP/Ph. Eur.) Salmeterol Xinafoate (USP/Ph. Eur.) Sertraline Hydrochloride (IH/USP/Ph. Eur.) Sumatriptan Succinate (USP/Ph. Eur.) Sorafenib Tosylate (IH) Trihexylphenidyl Hydrochloride (USP/Ph.Eur.) Zoledronic Acid (IH) Zolmitriptan (IH) Abacavir Sulphate Ph. Eur. Abacavir Sulphate USP Allopurinol USP Atorvastatin Calcium USP Baclofen USP Clozapine USP Fexofenadine Hydrochloride USP Gabapentin USP Naproxen USP Naproxen Sodium USP Pantoprozole Sodium Sesquihydrate USP Propafenone Hydrochloride USP Risedronate Sodium USP Ritonavir USP Sildenafil USP Trazadone Hydrochloride USP Valsartan USP Zidovudine USP Alendronate Sodium USP Alendronate Sodium Ph.Eur Allopurinol Ph.Eur Ambrisentan IH Atazanavir Sulfate IH Atorvastatin Calcium trihydrate Ph. Eur Baclofen Ph. Eur Clozapine Ph. Eur Deferasirox IH 23.06.2016
Load more

Recommended publications
  • Isopropamide Iodide
    www.chemicalland21.com ISOPROPAMIDE IODIDE SYNONYMS (3-Carbamoyl-3,3-diphenylpropyl)diisopropylmethylammonium iodide; 2,2-Diphenyl-4- diisopropylaminobutyramide methiodide; 4-(Diisopropylamino)-2,2-diphenylbutyramide methiodide; gamma-(Aminocarbonyl)-N-methyl-N,N-bis(1-methylethyl)-gamma-phenylbenzenepropanaminium iodide; Iodure d'isopropamide; Ioduro de isopropamida; Isopropamide ioduro; Isopropamidi iodidum; Isoproponum iodide; PRODUCT IDENTIFICATION CAS RN 71-81-8 EINECS RN 200-766-8 FORMULA C23H33IN2O MOL WEIGHT 480.43 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to off-white powder MELTING POINT 199 C BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Isopropamide is a long-acting anticholinergic and antimuscarinic drug of quaternary ammonium structure. It is used in the form of the iodide, (also bromide or chloride) to treat peptic ulcer and to suppress gastric secretion other gastrointestinal disorders. Brands of Isopropamide drugs: Darbid Dipramide Isamide Marygin-M Piaccamide Priamide Priazimide Sanulcin Tyrimide Quaternary ammonium anticholinergics (Synthetic) ATC Code Product CAS RN. A03AB01 Benzilonium bromide 1050-48-2 A03AB02 Glycopyrrolate 596-51-0 A03AB03 Oxyphenonium 14214-84-7 A03AB04 Penthienate 22064-27-3 A03AB05 Propantheline 50-34-0 A03AB06 Otilonium bromide 26095-59-0 A03AB07 Methantheline 5818-17-7 Please mail us if you want to sell your product or need to buy some products) www.chemicalland21.com ISOPROPAMIDE IODIDE A03AB08 Tridihexethyl 60-49-1 A03AB09 Isopropamide 7492-32-2 A03AB10 Hexocyclium 6004-98-4 A03AB11 Poldine 596-50-9 A03AB12 Mepenzolic acid 25990-43-6 A03AB13 Bevonium 33371-53-8 A03AB14 Pipenzolate 13473-38-6 A03AB15 Diphemanil methylsulfate 62-97-5 A03AB16 (2-Benzhydryloxyethyl)diethyl-methylammonium iodide A03AB17 Tiemonium iodide 144-12-7 A03AB18 Prifinium bromide 4630-95-9 A03AB19 Timepidium bromide 35035-05-3 A03AB21 Fenpiverinium bromide 125-60-0 03AB53 Oxyphenonium, combinations STABILITY AND REACTIVITY STABILITY Stable under normal conditions.
    [Show full text]
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and Their Generics)
    Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and their generics) Drospirenone is a progestin component of some birth control pills that does some blocking of testosterone (the "male hormone" that women have, too, and the hormone that can be a part of making acne worse). This is why drospirenone-containing birth control pills are especially good at helping acne (and why they can theoretically help hirsutism and female-pattern scalp hair loss as well). Drospirenone is also a mild diuretic and is why these birth control pills do not cause the water weight gain that some birth control pills can. Any birth control pill can theoretically help acne just by evening out hormonal fluctuations, but for many birth control pills, the effects on acne is very minimal. Which birth control pills are most likely to help acne? Some birth control pills are more like testosterone and some are less like testosterone. The ones that are less like testosterone can theoretically help acne more. The drospirenone-containing birth control pills go one step further by blocking testosterone, and may show the most benefit on clearing acne. Drospirenone is a progestin that is derived from 17-alpha-spironolactone and is chemically related to the diuretic spironolactone. Spironolactone is a diuretic (used for high blood pressure) that is sometimes used off-label for the treatment of acne, hirsutism or female-pattern hair loss. Often people say that a drospirenone-containing birth control pill may be equivalent to 25mg of spironolactone. Risks : Any estrogen-containing birth control pill increases the risk of a high blood pressure, stroke, or other life-threatening blood clot, and one study showed possibly a slightly higher risk with a drospirenone-containing birth control pill.
    [Show full text]
  • An Approach to the Patient with a Dry Mouth
    MedicineToday 2014; 15(4): 30-37 PEER REVIEWED FEATURE 2 CPD POINTS An approach to the patient with a dry mouth Key points • The subjective complaint of ELHAM AFLAKI MD; TAHEREH ERFANI MD; NICHOLAS MANOLIOS MB BS(Hons), PhD, MD, FRACP, FRCPA; xerostomia needs to be MARK SCHIFTER FFD, RCSI(Oral Med), FRACDS(Oral Med) differentiated from true salivary hypofunction. Dry mouth is a common and disabling problem. After exclusion of treatable • Salivary hypofunction can significantly reduce quality causes, treatment is symptomatic to prevent the consequences of salivary of life through its adverse hypofunction, such as tooth decay and infection of the oral mucosa. effects on taste, mastication, swallowing, cleansing of the erostomia, or the subjective feeling of neuropathic-induced orofacial dysaesthesia) mouth, killing of microbes a dry mouth, is a common complaint. and psychological and psychiatric disorders, and speech. It is often a consequence of salivary such as anxiety and depression. • Salivary hypofunction is a hypofunction (hyposalivation), in substantive risk factor for X which there is objective evidence of reduced NORMAL SALIVA PRODUCTION dental caries, oral mucosal salivary output or qualitative changes in saliva. Under normal physiological conditions, the disease and infection, Typically, patients complain of oral dryness salivary glands produce 1000 to 1500 mL of particularly oral candidiasis. only when salivary secretion is reduced by more saliva daily as an ultrafiltrate from the circu- • Patients should be than half.1 As saliva has a crucial role in taste lating plasma. Therefore, simple dehydration investigated for contributory perception, mastication, swallowing, cleansing reduces saliva production. The parotid glands and underlying causes, of the mouth, killing of microbes and speech, are the major source of serous saliva (60 to 65% which include drugs and abnormalities in saliva production can signif- of total saliva volume), producing the stimu- rheumatological diseases.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No
    WITHOUTUS010307409B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 307 ,409 B2 Chase et al. (45 ) Date of Patent: Jun . 4 , 2019 ( 54 ) MUSCARINIC COMBINATIONS AND THEIR (52 ) U . S . CI. USE FOR COMBATING CPC . .. .. A61K 31/ 4439 (2013 . 01 ) ; A61K 9 /0056 HYPOCHOLINERGIC DISORDERS OF THE (2013 . 01 ) ; A61K 9 / 7023 ( 2013 . 01 ) ; A61K CENTRAL NERVOUS SYSTEM 31 / 166 ( 2013 . 01 ) ; A61K 31 / 216 ( 2013 . 01 ) ; A61K 31 /4178 ( 2013 .01 ) ; A61K 31/ 439 (71 ) Applicant: Chase Pharmaceuticals Corporation , ( 2013 .01 ) ; A61K 31 /44 (2013 . 01 ) ; A61K Washington , DC (US ) 31/ 454 (2013 .01 ) ; A61K 31/ 4725 ( 2013 .01 ) ; A61K 31 /517 (2013 .01 ) ; A61K 45 / 06 ( 72 ) Inventors : Thomas N . Chase , Washington , DC (2013 . 01 ) (US ) ; Kathleen E . Clarence -Smith , ( 58 ) Field of Classification Search Washington , DC (US ) CPC .. A61K 31/ 167 ; A61K 31/ 216 ; A61K 31/ 439 ; A61K 31 /454 ; A61K 31 /4439 ; A61K (73 ) Assignee : Chase Pharmaceuticals Corporation , 31 /4175 ; A61K 31 /4725 Washington , DC (US ) See application file for complete search history. ( * ) Notice : Subject to any disclaimer, the term of this (56 ) References Cited patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . U . S . PATENT DOCUMENTS 5 ,534 ,520 A 7 / 1996 Fisher et al. ( 21) Appl . No. : 15 /260 , 996 2008 /0306103 Al 12 /2008 Fisher et al. 2011/ 0021503 A1* 1/ 2011 Chase . .. A61K 31/ 27 ( 22 ) Filed : Sep . 9 , 2016 514 / 215 2011/ 0071135 A1 * 3 / 2011 Chase . .. .. .. A61K 31/ 166 (65 ) Prior Publication Data 514 / 215 2011 /0245294 Al 10 / 2011 Paborji et al.
    [Show full text]
  • Evidence Review E: Pain Management
    National Institute for Health and Care Excellence Final Renal and ureteric stones: assessment and management Pain management NICE guideline NG118 Intervention evidence review (E) January 2019 Final This evidence review was developed by the National Guideline Centre FINAL Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian. Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.
    [Show full text]
  • Anthem Blue Cross Drug Formulary
    Erythromycin/Sulfisoxazole (generic) INTRODUCTION Penicillins ...................................................................... Anthem Blue Cross uses a formulary Amoxicillin (generic) (preferred list of drugs) to help your doctor Amoxicillin/Clavulanate (generic/Augmentin make prescribing decisions. This list of drugs chew/XR) is updated quarterly, by a committee Ampicillin (generic) consisting of doctors and pharmacists, so that Dicloxacillin (generic) the list includes drugs that are safe and Penicillin (generic) effective in the treatment of diseases. If you Quinolones ..................................................................... have any questions about the accessibility of Ciprofloxacin/XR (generic) your medication, please call the phone number Levofloxacin (Levaquin) listed on the back of your Anthem Blue Cross Sulfonamides ................................................................ member identification card. Erythromycin/Sulfisoxazole (generic) In most cases, if your physician has Sulfamethoxazole/Trimethoprim (generic) determined that it is medically necessary for Sulfisoxazole (generic) you to receive a brand name drug or a drug Tetracyclines .................................................................. that is not on our list, your physician may Doxycycline hyclate (generic) indicate “Dispense as Written” or “Do Not Minocycline (generic) Substitute” on your prescription to ensure Tetracycline (generic) access to the medication through our network ANTIFUNGAL AGENTS (ORAL) _________________ of community
    [Show full text]
  • Download PDF File
    Ginekologia Polska 2019, vol. 90, no. 9, 520–526 Copyright © 2019 Via Medica ORIGINAL PAPER / GYNECologY ISSN 0017–0011 DOI: 10.5603/GP.2019.0091 Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality — a preliminary study Anna Fuchs, Aleksandra Matonog, Paulina Sieradzka, Joanna Pilarska, Aleksandra Hauzer, Iwona Czech, Agnieszka Drosdzol-Cop Department of Pregnancy Pathology, Department of Woman’s Health, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland ABSTRACT Objectives: Using anti-androgenic contraception is one of the methods of birth control. It also has a significant, non-con- traceptive impact on women’s body. These drugs can be used in various endocrinological disorders, because of their ability to reduce the level of male hormones. The aim of our study is to establish a correlation between taking different types of anti-androgenic drugs and intensity of hirsutism, acne, menstrual pain intensity and sexuality . Material and methods: 570 women in childbearing age that had been using oral contraception for at least three months took part in our research. We examined women and asked them about quality of life, health, direct causes and effects of that treatment, intensity of acne and menstrual pain before and after. Our research group has been divided according to the type of gestagen contained in the contraceptive pill: dienogest, cyproterone, chlormadynone and drospirenone. Ad- ditionally, the control group consisted of women taking oral contraceptives without antiandrogenic component. Results: The mean age of the studied group was 23 years ± 3.23. 225 of 570 women complained of hirsutism.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu Et Al
    US 2003O1086O2A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0108602 A1 Chu et al. (43) Pub. Date: Jun. 12, 2003 (54) TABLETS AND METHODS FOR MODIFIED (22) Filed: Jul. 8, 2002 RELEASE OF HYDROPHILIC AND OTHER ACTIVE AGENTS Related U.S. Application Data (75) Inventors: James Shunnan Chu, Palo Alto, CA (63) Continuation of application No. 09/599,102, filed on (US); Yisong Yang, Sunnyvale, CA May 19, 2000, now Pat. No. 6,419,954. (US); Joseph A. Fix, Half Moon Bay, CA (US) Publication Classification Correspondence Address: (51) Int. Cl. ............................................... A61K 9/20 TOWNSEND AND TOWNSEND AND CREW, (52) U.S. Cl. .............................................................. 424/465 LLP TWO EMBARCADERO CENTER EIGHTH FLOOR (57) ABSTRACT SAN FRANCISCO, CA 94111-3834 (US) (73) Assignee: Yamanouchi Pharma Technologies, The invention provides a tablet and methods for making the Inc., Palo Alto, CA (US) tablet comprising a gel-forming material and at least one particle comprising an active agent in contact with a coating (21) Appl. No.: 10/191,979 material to modify release of the active agent. Patent Application Publication Jun. 12, 2003 Sheet 1 of 11 US 2003/0108602 A1 (O) N 3(O) 2(O) A/G /A Patent Application Publication Jun. 12, 2003. Sheet 2 of 11 US 2003/0108602 A1 O / O2 OOO OO O Q(SO39 O KC O () i88. OOO OO Okk (ki (k) <k. SJS19O OO <! o O OSS) O O 33 kg) O<< 3k 32 "ooO O & : A/6, 2O Patent Application Publication Jun. 12, 2003 Sheet 3 of 11 US 2003/0108602 A1 Active POWCer (Cevimeline HCI) Formulation Parameters -Pretreatment of Active -Binder: Solid or Solution Binder -% Content of Binder (HPC or PEO/PEG) -Amount of Water Process Parameters -Equipment Selection -Spray Technique Pelletization -Product Temperature (Granulation) -Drying Procedure Process -Milling Technique -High Shear G -Fluid-Bed G In-Process Tests -Yield Active Pellet/Granules -Physical Characteristics -ASSay FIG.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In
    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
    [Show full text]